Alnylam Holds Hands With a New Fella

It looks like the reality of the risk of failure for RNAi drugs has finally set in for big pharma.

After landing substantial deals with Biogen Idec (Nasdaq: BIIB  ) , Medtronic (NYSE: MDT  ) , Novartis (NYSE: NVS  ) , and Merck (NYSE: MRK  ) , who did Alnylam (Nasdaq: ALNY  ) finally get to partner its lead compound, respiratory syncytial virus (RSV) infection treatment ALN-RSV01? ... Cubist Pharmaceuticals (Nasdaq: CBST  ) .

Cubist? Really? I mean, I don't have anything against the company. Heck, it's one of my top scorers in Motley Fool CAPS, but we're not exactly talking a powerhouse here. The company's market cap isn't that much larger than Alnylam's. Not, like, Merck-sized bigger.

And the deal doesn't look like it's benefiting Alnylam that much either. Alnylam is getting only $20 million up front and $82.5 million in potential milestone payments in exchange for giving up 50% of its U.S. stake. Cubist gets full rights to the drug outside of North America and Asia, with Alnylam entitled to double-digit royalties on those net sales. That seems awfully low given that the potential for ALN-RSV01 is huge, especially if it can fight RSV and not just prevent it. AstraZeneca's (NYSE: AZN  ) prophylactic RSV treatment, Synagis, is on pace to be a blockbuster with sales of $724 million in the first nine months of last year.

My problem with RNAi has never been its potential. Instead, it's that the technology, which lowers the stability of RNA and can effectively shut down protein production of a specific gene, hasn't really been proven to work in humans yet. Those monster deals that pharmaceutical companies signed in recent years just seemed too risky to me for a technology that might not work or might take years to refine. Gene therapy anyone?

I may be reading more into Alnylam's deal than I should, but it looks to me like big pharma has finally come to its senses and passed on RNAi, at least with this one.

More Foolishness on high risk/high reward:

Let us know what you think in the Motley Fool CAPS investor-intelligence community. Make an out- or underperform call on these companies; post a pitch about whether you think RNAi is the hot new thing or an overpriced dud. It's free. It's fun. And, it's Foolish. 

Fool contributor Brian Orelli, Ph.D., has been breaking in and out of the top 1% of CAPS for months now; he's currently out with a rating of 98.97. He doesn't own shares of any company mentioned in this article. Biogen Idec is a Stock Advisor pick. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 807389, ~/Articles/ArticleHandler.aspx, 4/21/2014 3:23:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 days ago Sponsored by:
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASD 4,095.52 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/17/2014 3:59 PM
ALNY $53.86 Down -0.75 -1.37%
Alnylam Pharmaceut… CAPS Rating: ***
AZN $63.49 Down -0.04 -0.06%
AstraZeneca plc (A… CAPS Rating: ****
BIIB $290.54 Down -0.94 -0.32%
Biogen Idec CAPS Rating: ****
CBST $63.95 Up +0.02 +0.03%
Cubist Pharmaceuti… CAPS Rating: ****
MDT $58.55 Up +0.06 +0.10%
Medtronic, Inc. CAPS Rating: ****
MRK $56.47 Up +0.21 +0.37%
Merck & Co., Inc. CAPS Rating: ***
NVS $84.67 Up +0.26 +0.31%
Novartis CAPS Rating: *****

Advertisement